Print Page    E-mail Page    RSS    E-mail Alerts 

Investors

Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary diseases by developing innovative therapies and to do so while serving the best interests of our shareholders.

We are currently developing three product candidates under our INOpulse pro... more >

Stock Quotemore >
$1.11
0.00 (0.00%)
Bellerophon (Nasdaq: BLPH)
Data as of 12/13/18 9:32 a.m. ET
Minimum 20 minute delay
Recent Newsmore >
11/07/18
Bellerophon Provides Business Update and Reports Third Quarter 2018 Financial Results
WARREN, N.J., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the third quarter ended September 30, 2018. “We are pleased to have completed enrollment in the first cohort of our inhaled nitric oxide for pulmonary fibrosis (iNO-PF) Phase 2b study in pulmonary hypertension associated with interstitial lung disease (PH-I... 
10/09/18
Bellerophon Provides Update on INOpulse® Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Enrollment of the Planned 40 Subjects Completed, with Top-line Data Expected in January 2019 WARREN, N.J., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided an update on the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH... 
08/29/18
Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference
WARREN, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 20th Annual Global Investment Conference, taking place September 4-6, 2018, at the St. Regis New York Hotel. Bellerophon Presentation Details Date:  Wednesday, September 5 Time:  9:10am Eastern Tim... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources